CD38 expression on gluten-specific T cells is a robust marker of gluten re-exposure in coeliac disease.
ADP-ribosyl Cyclase 1
/ genetics
Adult
Aged
Antibodies
/ immunology
Biomarkers
Celiac Disease
/ diagnosis
Cytokines
/ metabolism
Female
Gene Expression
Glutens
/ adverse effects
HLA Antigens
/ genetics
Humans
Immunoglobulin A
/ immunology
Immunoglobulin G
/ immunology
Male
Membrane Glycoproteins
/ genetics
Middle Aged
Protein Binding
T-Lymphocytes
/ immunology
Young Adult
CD38
CD4
Coeliac disease
IL-2
T cells
activation marker
gluten
interleukin
kinetics
tetramers
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
04
06
2019
accepted:
06
08
2019
entrez:
17
12
2019
pubmed:
17
12
2019
medline:
1
7
2020
Statut:
ppublish
Résumé
Increasing efforts are being put into new treatment options for coeliac disease (CeD), a chronic disorder of the small intestine induced by gluten. Interleukin-2 (IL-2) and gluten-specific CD4 + T cells increase in the blood after four hours and six days, respectively, following a gluten challenge in CeD patients. These responses are unique to CeD and are not seen in controls. We aimed to evaluate different markers reflecting a recall response to gluten exposure that may be used to monitor therapy. CeD patients on a gluten-free diet underwent a one- ( The frequency of gut-homing, tetramer-binding, CD4 + effector memory T (tetramer + β7 + T The optimal time points for monitoring therapy response in CeD after a three-day oral gluten challenge is four hours for plasma IL-2 or six to eight days for the frequency of tetramer + β7 + T
Sections du résumé
Background
Increasing efforts are being put into new treatment options for coeliac disease (CeD), a chronic disorder of the small intestine induced by gluten. Interleukin-2 (IL-2) and gluten-specific CD4 + T cells increase in the blood after four hours and six days, respectively, following a gluten challenge in CeD patients. These responses are unique to CeD and are not seen in controls. We aimed to evaluate different markers reflecting a recall response to gluten exposure that may be used to monitor therapy.
Methods
CeD patients on a gluten-free diet underwent a one- (
Results
The frequency of gut-homing, tetramer-binding, CD4 + effector memory T (tetramer + β7 + T
Conclusions
The optimal time points for monitoring therapy response in CeD after a three-day oral gluten challenge is four hours for plasma IL-2 or six to eight days for the frequency of tetramer + β7 + T
Identifiants
pubmed: 31839959
doi: 10.1177/2050640619874183
pii: 10.1177_2050640619874183
pmc: PMC6894002
doi:
Substances chimiques
Antibodies
0
Biomarkers
0
Cytokines
0
HLA Antigens
0
Immunoglobulin A
0
Immunoglobulin G
0
Membrane Glycoproteins
0
Glutens
8002-80-0
CD38 protein, human
EC 3.2.2.5
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Banques de données
ClinicalTrials.gov
['NCT02464150']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1337-1344Informations de copyright
© Author(s) 2019.
Références
United European Gastroenterol J. 2019 Jun;7(5):583-613
pubmed: 31210940
United European Gastroenterol J. 2014 Aug;2(4):268-78
pubmed: 25083284
Best Pract Res Clin Gastroenterol. 2015 Jun;29(3):413-23
pubmed: 26060106
Nat Rev Dis Primers. 2019 Jan 10;5(1):3
pubmed: 30631077
Gut. 2018 Aug;67(8):1410-1424
pubmed: 29440464
Dig Dis. 2015;33(2):115-21
pubmed: 25925911
Lancet. 2002 Feb 23;359(9307):696-700
pubmed: 11879884
J Leukoc Biol. 2005 Apr;77(4):513-21
pubmed: 15618297
Am J Gastroenterol. 2011 Jun;106(6):1147-59
pubmed: 21386831
Nat Rev Gastroenterol Hepatol. 2018 Oct;15(10):583-584
pubmed: 29973675
Nat Med. 2000 Mar;6(3):337-42
pubmed: 10700238
Nat Rev Immunol. 2013 Apr;13(4):294-302
pubmed: 23493116
Scand J Gastroenterol. 2012 Jul;47(7):770-7
pubmed: 22519894
Am J Gastroenterol. 2011 Jul;106(7):1318-24
pubmed: 21364548
Gastroenterology. 2018 Mar;154(4):886-896.e6
pubmed: 29146521
Sci Adv. 2019 Aug 07;5(8):eaaw7756
pubmed: 31457091
Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2831-6
pubmed: 17307878
Eur J Immunol. 1993 Oct;23(10):2407-11
pubmed: 8405040
Gut. 2018 Sep;67(9):1606-1613
pubmed: 28779027
J Immunol. 2016 Mar 15;196(6):2819-26
pubmed: 26895834
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):13073-8
pubmed: 23878218
Immunity. 1997 Sep;7(3):315-24
pubmed: 9324352
J Immunol. 2017 Apr 15;198(8):3005-3014
pubmed: 28373482
Blood. 2008 Apr 1;111(7):3653-64
pubmed: 18212246
Gut. 2014 Aug;63(8):1210-28
pubmed: 24917550
Nat Rev Immunol. 2012 Feb 17;12(3):180-90
pubmed: 22343569
J Immunol. 1997 Jul 1;159(1):193-205
pubmed: 9200455
Scand J Gastroenterol. 2003 Sep;38(9):947-54
pubmed: 14531531
J Immunol. 2001 Nov 1;167(9):4861-8
pubmed: 11673490